Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study

• Main Authors: Barbara Ruaro (Author), Andrea Salotti (Author), Nicolò Reccardini (Author), Stefano Kette (Author), Beatrice Da Re (Author), Salvatore Nicolosi (Author), Umberto Zuccon (Author), Marco Confalonieri (Author), Lucrezia Mondini (Author), Riccardo Pozzan (Author), Michael Hughes (Author), Paola Confalonieri (Author), Francesco Salton (Author)
• Format: Book
• Published: MDPI AG, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background. Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with rapidly progressive evolution and an unfavorable outcome. Nintedanib (NTD) is an antifibrotic drug that has been shown to be effective in slowing down the progression of the disease. The aim of our study was...